Abstracts tagged "autoimmune diseases"

Abstract Number: 1589 • ACR Convergence 2021
COVID-19 Vaccine Hesitancy in Rheumatology Patients
Rebecca Sadun¹, Amanda Eudy¹, Jennifer Rogers¹, Kai Sun², Lisa Criscione-Schreiber², Mithu Maheswaranathan², Jayanth Doss¹ and Megan Clowse³, ¹Duke University, Durham, NC, ²Duke University School of Medicine, Durham, NC, ³Duke University, Chapel Hill, NC
Background/Purpose: Patients with rheumatic diseases on certain immunosuppressant medications are known to be at higher risk for severe COVID-19. The ACR recommends COVID-19 vaccination for…
Abstract Number: 1742 • ACR Convergence 2021
Efficacy of Anifrolumab in Serological Subgroups of Patients with SLE Participating in 2 Phase 3 Trials
Ian N. Bruce¹, Ronald Van Vollenhoven², Yoshiya Tanaka³, Eric Morand⁴, Richard Furie⁵, Konstantina Psachoulia⁶, Emmanuelle Maho⁷, Catharina Lindholm⁸, Christi Kleoudis⁹ and Raj Tummala⁶, ¹University of Manchester and NIHR Manchester Biomedical Research Centre, Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom, ²Amsterdam Rheumatology and Immunology Center, Amsterdam, Netherlands, ³University of Occupational and Environmental Health, Kitakyushu, Japan, ⁴Monash University, Melbourne, Australia, ⁵Zucker School of Medicine at Hofstra/Northwell Health, Great Neck, NY, ⁶BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, ⁷BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom, ⁸BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden, ⁹BioPharmaceuticals R&D, AstraZeneca, Durham, NC
Background/Purpose: In the TULIP-2 and TULIP-1 trials of patients with SLE, the type I IFN receptor mAb anifrolumab resulted in higher BILAG–based Composite Lupus Assessment…
Abstract Number: 0092 • ACR Convergence 2021
Clinical Outcomes of Patients with Systemic Rheumatic Diseases Hospitalized for COVID-19 at a Large Academic Center in New York City
Caroline Siegel¹, Jacky Choi², Debra D'Angelo², Paul Christos², Lindsay Lally¹, Parag Goyal², Lisa Mandl¹ and Medha Barbhaiya¹, ¹Hospital for Special Surgery, New York, NY, ²Weill Cornell Medicine, New York, NY
Background/Purpose: While patients with systemic rheumatic diseases (SRDs) are in general more vulnerable to infections due to their underlying immune dysregulation and immunomodulatory therapies, data…
Abstract Number: 0187 • ACR Convergence 2021
Safety and Tolerability of Nintedanib in Patients with Autoimmune Disease-Related Interstitial Lung Diseases: Pooled Data from the SENSCIS and INBUILD Trials
Vanessa Smith¹, Shervin Assassi², Yannick Allanore³, Lazaro Loaiza⁴, Inga Tschoepe⁵, Madhu Kanakapura⁴ and Elizabeth Volkmann⁶, ¹Department of Rheumatology and Internal Medicine, Ghent University Hospital, Ghent, Belgium, ²University of Texas McGovern Medical School at Houston, Houston, TX, ³Department of Rheumatology A, Descartes University, APHP, Cochin Hospital, Paris, France, ⁴Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim, Germany, ⁵Elderbrook Solutions, Bietigheim-Bissingen, Germany, Bietigheim-Bissingen, Germany, ⁶Department of Medicine, Division of Rheumatology, University of California, David Geffen School of Medicine, Los Angeles, CA
Background/Purpose: The efficacy and safety of nintedanib have been investigated in patients with systemic sclerosis-associated ILD (SSc-ILD) in the SENSCIS trial and in patients with…
Abstract Number: 0437 • ACR Convergence 2021
Factors Associated with Reduced Immunogenicity of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Autoimmune Inflammatory Rheumatic Diseases (AIIRD) Treated with Rituximab
Victoria Furer¹, Tali Eviatar², Devy Zisman³, Hagit Peleg⁴, Daphna Paran⁵, David Levartovsky¹, Ilana Kaufman⁶, Michael Zisapel¹, Ofir Elalouf⁷, Roni Meidan¹, Adi Broyde⁸, Ari Polachek⁹, Jonathan Wollman⁷, Katya Meridor¹⁰, Hila Nochomovitz¹, Adi Silberman¹, Dana Rosenberg¹, Joy Feld¹¹, Amir Haddad¹², Tal Gazitt¹³, Muna Elias³, Nizar Hijaze¹⁴, Fadi Kharouf⁴, Gabi Shefer¹, Orly Sharon¹, Sara Pel¹, Sharon Nevo¹ and Ori Elkayam¹⁵, ¹Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, ²Tel Aviv Sourasky Medical Center, Givataim, Israel, ³Carmel Medical Center, Haifa, Israel, ⁴Hadassah Medical Center, Jerusalem, Israel, ⁵Tel Aviv Sourasky Medical Center-Ichilov Hospital, Even Yehuda, Israel, ⁶Tel Aviv Sourasky Medical Center, Petach Tiqwa, Israel, ⁷Tel Aviv Medical Center, Herzliya, Israel, ⁸Tel Aviv Sourasky Medical Center, KIBBUTZ GIVAT HAIM I, Israel, ⁹Sourasky Medical Center, Petah-Tikva, Israel, ¹⁰Tel Aviv Sourasky Medical Center, Kfar Saba, Israel, ¹¹Carmel and Zvulun Medical Centre, Haifa, Israel, ¹²Carmel Medical Centre, Haifa, Israel, ¹³Carmel Hospital, Haifa, Israel, ¹⁴Carmel medical centre, Tamra, Israel, ¹⁵Tel Aviv Medical Center, Tel Aviv, Israel
Background/Purpose: Rituximab (RTX) has been associated with impaired humoral response to vaccination. This study aim was to identify the predictors for a lack of humoral…
Abstract Number: 0634 • ACR Convergence 2021
Correlation Between the Functional Component of the Multidimensional Health Assessment Questionnaire (FN), Modified Health Assessment Questionnaire (MHAQ), Health Assessment Questionnaire II (HAQ-II) and a Single Functional Question (PF) in Patients with Rheumatic Disease
Andrea Healy¹, Johny Fares¹, Martin Bergman², Kaleb Michaud³, Alison Petro³ and Harlan Sayles³, ¹Main Line Health, Wynnewood, PA, ²Martin Jan Bergman, MD, Ridley Park, PA, ³University of Nebraska Medical Center, Omaha, NE
Background/Purpose: There has been significant work developing questionnaires to find effective and reliable ways of characterizing the functional status of patients, to track disease progression…
Abstract Number: 0970 • ACR Convergence 2021
Hippo Signaling Is a Novel Regulator of Apoptosis and Photosensitivity in Lupus Keratinocytes
Grace Hile¹, Patrick Coit², Bin Xu¹, Shannon Estadt¹, Jacob Martens³, Rachael Wasikowski¹, Lam Tsoi¹, Ramiro Iglesias-Bartolome⁴, Celine Berthier¹, Allison Billi⁵, Johann Gudjonsson⁵, Amr Sawalha² and J. Michelle Kahlenberg¹, ¹University of Michigan, Ann Arbor, MI, ²University of Pittsburgh, Pittsburgh, PA, ³Graduate Program in Immunology, University of Michigan, Ann Arbor, MI, USA, Ann Arbor, MI, ⁴NIH, National Cancer Institute, Bethesda, MD, ⁵Department of Dermatology, University of Michigan, Ann Arbor, MI
Background/Purpose: Skin inflammation and photosensitivity are common manifestations of cutaneous (CLE) and systemic lupus erythematosus (SLE), yet the mechanisms underlying heightened cell death and epidermal…
Abstract Number: 1096 • ACR Convergence 2021
CSF-specific CD8 T Cell Clonal Expansion in Neurosarcoidosis
Michael Paley¹, Brandi Baker², Steven Dunham³, Nicole Linskey³, Elisha Roberson³, David Clifford³ and Wayne Yokoyama³, ¹Washington University in St. Louis, Olivette, MO, ²Washington University in St. Louis, St. Louis, MO, ³Washington University School of Medicine, St. Louis, MO
Background/Purpose: Neuroinflammation is a severe manifestation of the systemic inflammatory disorders. Sarcoidosis, which leads to neurologic disease in 5-10 % of cases, has traditionally been…
Abstract Number: 1509 • ACR Convergence 2021
Pharmacological Inhibition of MALT1 Reverses Activation-Induced Metabolic Reprogramming and Ameliorates Autoimmune Pathogenesis in Multiple Animal Models of Chronic Inflammation
Subhabrata Biswas, Mya Steadman, Ynes Helou, Katherine Sellers, Keng Soh, Aditi Chalishazar, Mehmet Badur, Joanna DiSpirito, Brian DeChristopher, John Monroe, Dania Rabah, Barbara Fox and Andy Long, Rheos Medicines, Inc, Cambridge, MA
Background/Purpose: Current therapies for autoimmune and inflammatory diseases generally target select disease nodes, often failing to produce durable clinical remission. Chronic inflammation is associated with…
Abstract Number: 1596 • ACR Convergence 2021
Changes in Patient-Reported Outcome (PRO) Scores During the COVID-19 Pandemic: Data from the ArthritisPower Research Registry
Kelly Gavigan¹, Esteban Rivera¹, Jeffrey Curtis², Shilpa Venkatachalam¹, Laura Stradford³, David Curtis¹ and William Nowell¹, ¹Global Healthy Living Foundation, Upper Nyack, NY, ²Division of Clinical Immunology and Rheumatology, Department of Medicine, Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ³Global Healthy Living Foundation, Nyack, NY
Background/Purpose: The COVID-19 pandemic caused particular concern among patients with autoimmune and rheumatic disease (ARD) due to increased risk of infection, and heightened sense of…
Abstract Number: 1744 • ACR Convergence 2021
Improvement of Renal and Non-Renal SLE Outcome Measures on Sirolimus Therapy – a 21-year Follow-up Study of 73 Patients
Paramarajan Piranavan¹ and Andras Perl², ¹SUNY Upstate Medical University, Syracuse, NY, ²State University of New York, Syracuse, NY
Background/Purpose: The clinical heterogeneity of the SLE makes it often challenging for the treating clinician and also remains one of the many reasons behind failed…
Abstract Number: 0094 • ACR Convergence 2021
Characteristics Associated with Severe Outcomes in Patients with Systemic Rheumatic Diseases Hospitalized for COVID-19 in New York City
Caroline Siegel¹, Jacky Choi², Debra D'Angelo², Paul Christos², Lindsay Lally¹, Parag Goyal², Lisa Mandl¹ and Medha Barbhaiya¹, ¹Hospital for Special Surgery, New York, NY, ²Weill Cornell Medicine, New York, NY
Background/Purpose: Patients with systemic rheumatic diseases (SRD) are potentially at increased risk of severe outcomes from SARS-CoV-2 infection due to their underlying immune dysregulation and…
Abstract Number: 0188 • ACR Convergence 2021
Effect of Nintedanib on Categorical Changes in FVC in Patients with Progressive Fibrosing ILDs: Further Analyses of the INBUILD Trial
Toby M Maher¹, Stefania Cerri², Robert W Hallowell³, Dirk Koschel⁴, Janet Pope⁵, Leslie Tolle⁶, Heiko Mueller⁷, Klaus B Rohr⁸ and Yoshikazu Inoue⁹, ¹National Heart and Lung Institute, Imperial College London, UK, National Institute for Health Research Clinical Research Facility, Royal Brompton Hospital, London, UK, and Keck School of Medicine, University of Southern California, Los Angeles, CA, ²Center for Rare Lung Disease - Azienda Ospedaliero-Universitaria Policlinico di Modena, Modena, Italy, ³Massachusetts General Hospital, Boston, MA, USA, Boston, MA, ⁴Fachkrankenhaus Coswig, Coswig, Germany, Coswig, Germany, ⁵University of Western Ontario, London, ON, Canada, ⁶Department of Pulmonary Medicine and Critical Care Medicine, Cleveland Clinic, Cleveland, OH, ⁷Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany, ⁸Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim, Germany, ⁹Clinical Research Center, National Hospital Organization Kinki-Chuo Chest Medical Center, Sakai City, Osaka, Japan
Background/Purpose: In the INBUILD trial in subjects with progressive fibrosing interstitial lung diseases (ILDs) other than idiopathic pulmonary fibrosis (IPF), nintedanib reduced the rate of…
Abstract Number: 0439 • ACR Convergence 2021
Predictors of Rheumatic Immune-related Adverse Events and de Novo Inflammatory Arthritis After Immune Checkpoint Inhibitor-treatment for Cancer
Amy Cunningham-Bussel¹, Jiaqi Wang², Lauren Prisco³, Lily Martin², Kathleen Vanni², Alessandra Zaccardelli², Mazen Nasrallah⁴, Lydia Gedmintas², Lindsey MacFarlane⁵, Nancy Shadick⁶, Mark M. Awad⁷, Osama E. Rahma⁷, Nicole LeBoeuf⁸, Ellen Gravallese⁹ and Jeffrey Sparks², ¹Brigham and Women's, Brookline, MA, ²Brigham and Women's Hospital, Boston, MA, ³Brigham and Women's Hospital, Pound Ridge, MA, ⁴MGH, Somerville, MA, ⁵Brigham and Women's Hospital, Brookline, MA, ⁶Brigham & Women's Hospital, Boston, MA, ⁷Dana-Farber Cancer Institute, Boston, ⁸Brigham and Women's Hospital, Department of Dermatology, Boston, MA, ⁹Brigham and Women's Hospital, Harvard Medical School, Chestnut Hill, MA
Background/Purpose: Immune-related adverse events (irAEs) are a frequent and serious complication of immune checkpoint inhibitor (ICI) treatment for cancer, which can resemble primary rheumatic diseases.…
Abstract Number: 0649 • ACR Convergence 2021
Optimizing SARS-CoV-2 Vaccine Timing in Rituximab-Treated Patients with Autoimmune Rheumatic Diseases: A Quality Improvement Intervention
Daniel Magliulo¹, Stefanie Wade² and Vasileios Kyttaris³, ¹Beth Israel Deaconess Medical Center, Boston, MA, ²Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, ³BIDMC, Boston, MA
Background/Purpose: Experience with rituximab (RTX) in autoimmune rheumatic disease (AIRD) has shown a clear association with hypogammaglobulinemia, serious infections, and impaired humoral response to certain…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].